The MDR phenotype was first described in 1970 by Biedler & Riehm (1970) in Chinese hamster lung cells and P388 leukaemia cells. They described cross resistance of actinomycin-D resistant cells (derived by serial incubation in increasing drug concentration) with vinblastine and daunomycin. Subsequently other groups showed that this property was shared by other vinca alkaloids and anthracyclines, and also by etoposide (Seeber et al., 1982) . This group of drugs appears to share a common mechanism of cellular resistance, and recent data suggest that mitomycin-C could possibly be included in this list (Dorr et al., 1987) .
Ling's group in Toronto went on to demonstrate that this cross-resistance related to decreased intracellular drug accumulation (Juliano & Ling, 1976) , that this correlated in mammalian cell lines with the presence of a plasma membrane glycoprotein (P glycoprotein), of molecular weight 170,000 dalton (Kartner et al., 1983) , and that this could clearly be linked to amplification of specific genes encoding P glycoprotein (Riordan et al., 1985) . Amplification of other closely juxtaposed gene classes has also been detected in MDR cells, the product of one of which is the cytoplasmic protein, sorcin (Jongsma et al., 1987) . These observations have been confirmed by several other groups, and it has been noted that increased expression of the specific human gene encoding .P glycoprotein (the mdr-J gene) is a common phenomenon in MDR cells, with or without gene amplification (Shen et al., 1986) . The full length cDNA sequences encoding both human and mouse P glycoprotein have now been isolated and found to be virtually identical (Chen et al., 1986; Gros et al., 1986) . The structure, amino acid sequence and configuration of P glycoprotein within the cell membrane have now been elucidated, and its resemblance to bacterial transport proteins noted (Gerlach et al., 1986) . On the inside of the cell it possesses nucleotide-binding domains which probably bind ATP, and through which it appears to function in an energy-dependent manner.
Other groups have subsequently provided further evidence in support of the hypothesis that P glycoprotein acts as a drug efflux pump, with specific binding sites for drugs such as vinblastine (Safa et al., 1986) . Since drugs of the MDR family such as actinomycin D do not compete with vinblastine binding, more than one binding site on P glycoprotein may well be present (Cornwell et al., 1986) . Of particular importance however is the observation that other non-cytotoxic agents such as verapamil and quinidine do appear capable of competing for these binding sites with cytotoxic drugs of the MDR family (Cornwell et al., 1987) . This offers the exciting possibility of modulation of resistance clinically.
Recent information raises a further possibility, viz. that the phosphorylation state of P glycoprotein may modulate its function. Studies using an MDR human leukaemia cell line (K562/ADM) indicate that agents which restore drug sensitivity, such as verapamil, cause a significant increase in phosphorylation of P glycoprotein . It is possible that this occurs by activation of protein kinase C, but other kinases may well be involved, and further data are required to clarify the importance of these observations before they can be applied to other means of modulation.
Structurally the drugs involved in the MDR spectrum are dissimilar and they have different intracellular targets. However they are all hydrophobic co'mpounds derived from various natural products, and this may well account for the involvement of P glycoprotein in resistance to these agents. For increased expression, both of the mdr-J gene and of P glycoprotein itself has now been clearly shown in certain normal tissues (Fojo et al., 1987; Sugawara et al., 1988) . Immunohistochemical studies have confirmed localisation in organs such as the liver, kidney, intestine and adrenal gland, specifically in mucosal surfaces where a transport protein may be expected to function (Thiebaut et al., 1987) . Thus P glycoprotein may well act normally as a mechanism for protection against environmental toxins, and the hypothesis therefore is that resistant tumour cells expressing the MDR phenotype possess an enhanced form of a protective cellular mechanism which is also characteristic of certain normal cells.
But what does all this have to do with clinical drug resistance? The answer at present is quite unknown, but the availability of molecular probes for the human gene does provide a powerful tool for answering this question. When applied to the analysis of fresh tumour tissue from both treated and untreated patients, important information on the frequency with which the MDR phenotype occurs can be obtained. As well as searching for evidence of overexpression of mdr-1 RNA using the cDNA probe, some centres also include immunocytochemical studies using monoclonal antibodies derived against P glycoprotein (Bell et al., 1985) . Preparation of RNA from tumours requires careful collection procedures and rapid freezing, while the use of monoclonal antibodies may not be ideal if relevant epitopes are not recognised because of tissue processing. A recent development has been the development of an immunoperidoxase detection technique for P glycoprotein which would appear applicable to formalin fixed material (Chan et al., 1988) , and this raises the exciting possibility of large scale assessment of tumour material.
To date, consistently high levels of expression of mdr-l-MRNA or P glycoprotein have been obtained chiefly in those tumours derived from normal tissues which themselves have elevated levels of P glycoprotein, i.e. adrenal cancer, renal and colon cancer (Fojo et al., 1987) . Detectable levels have also been found in some cases of ovarian cancer (Bell et al., 1985) , breast cancer (Sugawara et al., 1988), sarcoma (Gerlach et al., 1987) and acute leukaemia (Ma et al., 1987) . Although in one report (in 2 leukaemia patients), a relationship betwen increasing P glycoprotein expression and clinical resistance may have existed (Ma et al., 1987) A particular problem in this type of clinical study is the difficulty in achieving plasma levels of the modulator which might be expected to have the desired effect on tumour cell drug transport. This applies particularly to verapamil, for which the concentration required to affect activity of drugs such as anthracyclines and vinca alkaloids is generally within the range of 2 to 6pM (Tsuruo et al., 1983a; Twentyman et al., 1986) . This is slightly higher than the concentration which may be achieved clinically with maximal oral administration (-1.5 gIM), although the observation that its major metabolite, norverapamil, which is present in the circulation in equimolar concentrations, possesses a comparable degree of enhancing ability in vitro, does mean that the clinical potential of verapamil may have been underestimated (Merry et al., 1987) . Nevertheless a range of other membrane active compounds have been identified as possessing similar modulating capacity. These include calcium antagonists and calmodulin inhibitors such as nifedipine, diltiazem and trifluoperazine (Tsuruo et al., 1983b, c) and more recently cyclosporin (Twentyman et al., 1987) and amiodarone (Chauffert et al., 1987) . These agents are mostly hydrophobic polar compounds, originally developed for another purpose, and therefore in some cases quite unsuitable in this context. However in some cases it appears that those concentrations which are capable of enhancing activity in vitro are achievable clinically. Examples include quinidine and bepridil (Tsuruo et al., 1984; Schuurhuis et al., 1987) and further clinical studies using this approach are under way. Clearly an important question in such studies is the potential for increased toxicity for normal tissues. One might expect the greatest likelihood of this in those tissues with the highest levels of P glycoprotein, but other interactions, such as a pharmacological effect of verapamil on adriamycin (Kerr et al., 1986) , may be more likely to have clinical impact.
Although the data described above do conform to a logical hypothesis which offers one explanation for the development of MDR, based on enhanced drug efflux, there remains uncertainty, as to the precise mechanisms involved. Skovsgaard's group have performed studies using both Ehrlich ascites tumour cells and P388 leukaemia cells, and have demonstrated enhanced endocytic activity associated with resistance to anthracyclines (Sehested et al., 1987a,b) . Their hypothesis is that following passive drug influx, drugs such as adriamycin which are weak bases may be trapped by protonation within acidic compartments such as endosomes (lysosomes) in resistant cells and then exported by energydependent exocytosis before reaching their site of action. This suggestion has also been made in a recent elegant review by Beck (1987) and supported by recent studies in an adriamycin-resistant human colon cancer cell line (Klohs & Steinkampf, 1988) . It is of interest that certain non-cytotoxic agents, again including drugs such as calmodulin inhibitors, are capable of disrupting vesicular traffic and restoring drug sensitivity to drug resistant cells (Sehested et al., 1987b) . It is indeed quite conceivable that P glycoprotein is involved in a drug transport system operating through acidic vesicles, although it has not yet been shown that P glycoprotein is present at sites other than the cell membrane. The proposition, however, is that drugs such as anthracyclines are trapped in endosomal vesicles which have P glycoprotein appropriately orientated in their membrane (Beck, 1987) . Clearly these suggestions indicate the need for continued research into the mechanisms of drug transport and its modulation.
Despite the wealth of data relating the MDR phenotype to P glycoprotein, examples of MDR cell lines in which no evidence of increased expression of mdr-J MRNA or P glycoprotein is found (Marsh & Center, 1987; Danks et al., 1987) . How might MDR arise in these circumstances? Two alternative hypotheses have been proposed, involving normal cellular enzymes: topoisomerases and glutathione-S-transferase.
Both topoisomerase I and topoisomerase II have been identified as important targets for cytotoxic drugs, particularly anthracyclines and the podophyllotoxins. In some cell lines resistance has been linked to altered activity, particularly of topoisomerase II (Pommier et al., 1986) . However the relevance of these observations to clinical drug resistance is quite unknown. Studies aimed at cloning the gene for topoisomerase II are well advanced, and once the probe becomes available, definitive statements on the importance of this mechanism may be possible.
The situation regarding glutathione-S-transference is even less clear. At least 12 isoenzymes have been described, and cDNA probes for specific genes, e.g. the human GST Pi isoenzyme, are becoming available. Increased levels of the anionic isoenzyme have previously been found in an adriamycinresistant human breast cancer cell line (Batist et al., 1986) , but the relevance of these data to drug resistance in general, much less to MDR, is not yet established, and studies using new molecular probes on fresh biopsy material will help to clarify the situation. The functions of GST include intracellular detoxification, and this activity may underly its involvement in resistance to a wide range of cytotoxic agents. In addition certain isoenzymes possess peroxidase activity, and it is conceivable that increased levels could be involved through that mechanism in protecting tumour cells from adriamycin toxicity, assuming that free radical generation is an important mechanism by which the drug exerts its effect (Sinha et al., 1987) .
As well as elevations in levels of GST, raised levels of cellular glutathione itself may be involved, at least in resistance to adriamycin if not in resistance to other drugg of the MDR family. Reduction of cellular glutathione, by buthionine sulfoximine (BSO) restores sensitivity to certain adriamycin resistant tumour cells, possibly by permitting the generation of toxic free radicals in cells which had previously been protected by glutathione (Hamilton et al., 1985) . In summary it is clear that the MDR story is a highly complex one. Non-clinicians may be forgiven for assuming that MDR is a description of the clinical observation that tumours often become resistant to several drugs simultaneously. It should be emphasised, however, that this is not the case and that MDR actually describes a specific experimental observation whose relevance to clinical resistance is not yet known. On balance it seems likely that tumours will possess several co-existent mechanisms for protecting themselves against cytotoxic drugs. It is a reasonable hypothesis that MDR is one of these, and that being so the potential now exists for a rational therapeutic attempt at tackling part of the problem of drug resistance.
